112 related articles for article (PubMed ID: 35837969)
1. Implementation of a Hepatocellular Carcinoma Screening Program for At-risk Patients Safety-Net Hospital: A Model for National Dissemination.
Lee RM; Darby R; Medin CR; Haser GC; Mason MC; Miller LS; Staley CA; Maithel SK; Russell MC
Ann Surg; 2022 Sep; 276(3):545-553. PubMed ID: 35837969
[TBL] [Abstract][Full Text] [Related]
2. The Evolving Landscape of Hepatocellular Carcinoma : A US Safety Net Collaborative Analysis of Etiology of Cirrhosis.
Lee RM; Gamboa AC; Turgeon MK; Yopp A; Ryon EL; Kronenfeld JP; Goel N; Wang A; Lee AY; Luu S; Hsu C; Silberfein E; Maithel SK; Russell MC
Am Surg; 2020 Jul; 86(7):865-872. PubMed ID: 32721171
[TBL] [Abstract][Full Text] [Related]
3. Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma.
Tavakoli H; Robinson A; Liu B; Bhuket T; Younossi Z; Saab S; Ahmed A; Wong RJ
Dig Dis Sci; 2017 Aug; 62(8):2174-2181. PubMed ID: 28474143
[TBL] [Abstract][Full Text] [Related]
4. Optimizing cancer care for hepatocellular carcinoma at a safety-net hospital: The value of a multidisciplinary disease management team.
Duininck G; Lopez-Aguiar AG; Lee RM; Miller L; Dariushnia S; Wu C; Alese OB; Lin JY; Wedd J; Adams A; Maithel SK; Russell MC
J Surg Oncol; 2019 Dec; 120(8):1365-1370. PubMed ID: 31642056
[TBL] [Abstract][Full Text] [Related]
5. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.
Davila JA; Henderson L; Kramer JR; Kanwal F; Richardson PA; Duan Z; El-Serag HB
Ann Intern Med; 2011 Jan; 154(2):85-93. PubMed ID: 21242365
[TBL] [Abstract][Full Text] [Related]
6. Low Rates of Retention Into Hepatocellular Carcinoma (HCC) Surveillance Program After Initial HCC Screening.
Robinson A; Tavakoli H; Cheung R; Liu B; Bhuket T; Wong RJ
J Clin Gastroenterol; 2019 Jan; 53(1):65-70. PubMed ID: 29629906
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach.
Mourad A; Deuffic-Burban S; Ganne-Carrié N; Renaut-Vantroys T; Rosa I; Bouvier AM; Launoy G; Cattan S; Louvet A; Dharancy S; Trinchet JC; Yazdanpanah Y; Mathurin P
Hepatology; 2014 Apr; 59(4):1471-81. PubMed ID: 24677195
[TBL] [Abstract][Full Text] [Related]
8. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
9. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System.
Tayob N; Richardson P; White DL; Yu X; Davila JA; Kanwal F; Feng Z; El-Serag HB
BMC Med Res Methodol; 2018 Jan; 18(1):1. PubMed ID: 29301497
[TBL] [Abstract][Full Text] [Related]
10. Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis.
Aby E; Phan J; Truong E; Grotts J; Saab S
J Clin Gastroenterol; 2019 Feb; 53(2):142-146. PubMed ID: 29912761
[TBL] [Abstract][Full Text] [Related]
11. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
Ioannou GN; Green PK; Beste LA; Mun EJ; Kerr KF; Berry K
J Hepatol; 2018 Nov; 69(5):1088-1098. PubMed ID: 30138686
[TBL] [Abstract][Full Text] [Related]
12. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
Cabibbo G; Petta S; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Negrini G; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Mega A; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Craxì A; Trevisani F; Cammà C;
J Hepatol; 2017 Jul; 67(1):65-71. PubMed ID: 28192185
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
14. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma.
Lu SN; Wang JH; Liu SL; Hung CH; Chen CH; Tung HD; Chen TM; Huang WS; Lee CM; Chen CC; Changchien CS
Cancer; 2006 Nov; 107(9):2212-22. PubMed ID: 17019738
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
[TBL] [Abstract][Full Text] [Related]
16. Mailed Outreach Program Increases Ultrasound Screening of Patients With Cirrhosis for Hepatocellular Carcinoma.
Singal AG; Tiro JA; Marrero JA; McCallister K; Mejias C; Adamson B; Bishop WP; Santini NO; Halm EA
Gastroenterology; 2017 Feb; 152(3):608-615.e4. PubMed ID: 27825963
[TBL] [Abstract][Full Text] [Related]
17. Screening for hepatocellular carcinoma in patients with advanced cirrhosis.
Chalasani N; Horlander JC; Said A; Hoen H; Kopecky KK; Stockberger SM; Manam R; Kwo PY; Lumeng L
Am J Gastroenterol; 1999 Oct; 94(10):2988-93. PubMed ID: 10520857
[TBL] [Abstract][Full Text] [Related]
18. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL;
Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748
[TBL] [Abstract][Full Text] [Related]
19. Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting.
Wong CR; Garcia RT; Trinh HN; Lam KD; Ha NB; Nguyen HA; Nguyen KK; Levitt BS; Nguyen MH
Dig Dis Sci; 2009 Dec; 54(12):2712-21. PubMed ID: 19876735
[TBL] [Abstract][Full Text] [Related]
20. Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort.
Parikh ND; Tayob N; Al-Jarrah T; Kramer J; Melcher J; Smith D; Marquardt P; Liu PH; Tang R; Kanwal F; Singal AG
JAMA Netw Open; 2022 Jul; 5(7):e2223504. PubMed ID: 35867057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
